Entering text into the input field will update the search result below

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Chetan Woodun profile picture
Chetan Woodun


  • Giant pharma Merck's co-developed oral coronavirus drug with Ridgeback Biotherapeutics has raised interest in non-injected vaccine alternatives.
  • The space was already occupied by Oramed, a clinical-stage biotech, whose oral vaccine is based on its POD technique, together with India's Premas Biotech COVID technology.
  • This is a huge market, but also a highly competitive one due to the sheer number of biotechs involved, but the Israeli company can use previous experience in diabetes and NASH.
  • Still, the fact that its shares have been adversely impacted after Merck's update shows that investors suffered from acidity when digesting the news.
  • I remain bullish on this diversified stock, with market action also showing that its shares have been less battered than for established COVID biotechs.

Medication of antiviral capsule(medicine drug) for treatment and prevention of new corona virus infection(COVID-19,novel coronavirus disease 2019 or nCoV 2019 from Wuhan. Pandemic infectious concept

sittithat tangwitthayaphum/iStock via Getty Images

After having covered a biotech developing a vaccine in the form of a nasal spray last month, I now cover Oramed Pharmaceuticals (NASDAQ:NASDAQ:ORMP), focused on developing an oral COVID-19 vaccine.

The shares of the

This article was written by

Chetan Woodun profile picture
As a tech-focused industry Research Analyst, my aim is to provide differentiated insights, whether it is for investing, trading, or informational reasons. For this purpose, I am not a classical equity researcher or fund manager, but, I come from the IT world as the founder of Keylogin Information and Technologies Co. Ltd. Thus, my research is often backed by analytics and I make frequent use of charts to support my position.I also invest, and thus, in this tumultuous market, I often look for strategies to preserve capital. As per my career history below, I have wide experience, initially as an implementer in virtualization and cloud, and I was subsequently a team leader and project lead, mostly working in telcos.I like to write around themes like automated supply chains, Generative AI, telcos Capex, the deflationary nature of software, semiconductors, etc and I am often contrarian. I have also covered biotechs.I have also been an entrepreneur in real estate ( a mediocre one), a business owner, and a farmer, and dedicate at least 5 hours per week to working on a non-profit basis. For this purpose, I help needy families by providing sponsored work and contributing peer reviews and opinions for enterprise tech.I have been investing for the last 25 years, initially in mutual or indexed funds before later opting for individual stocks. Got a lot of experience in the 2008/2009 downturn when I lost a lot due mostly to wrong advice. Since then I do my own research and have fallen in love with Seeking Alpha because of the unique perspectives it provides to someone investing hard-earned money as well as access to some of the best analysts.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This is an investment thesis and is intended for informational purposes. Investors are kindly requested to do additional research before investing.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (13)

Doc 224899 profile picture
ORMP -26% at the present time. No adverse news. >average volume. Is this evidence of new MEME stock status? Is it just the common fate of volatility in the vaccine stock sub-sector, and ORMP's time just came around today?

Long ORMP. Probably doubling down.
@Doc 224899 : Shorters at Parallax Bio (which has only 668 followers) published an Oramed attack article with refuted data and no author. If you were thinking about picking up some Oramed stock, now is the time. I would not be surprised to see it bounce back in a week or two.

It is painful to watch though...ugh.
Chetan Woodun profile picture
@Doc 224899 It’s because people fail to differentiate between Oramed’s jab-free oral Covid-19 vaccine and Merck/PFE drug.
I believe the Merck pill is for treatment and not as a vaccine. There continues to be a need for people to get their vaccine from other sources

India government has approved for the domestically produced vaccine to be exported. The domestic demand in India for the first vaccinations has largely been satisfied.

The oral vaccine from ORMP will be good booster if proven to be effective against variants and will have the advantage of being easier to administer

Certainly there are still many parts of the world that needs the first round of vaccine that is easy to administer and effective against new variants. ORMP would be the one to offer this excellent combination.
Is there not a Merk person who sits on the Oramed Board?
Great news- bringing exposure and news is good for all!
Great article!
U6439892 profile picture
New vaccine requirement is dead. ORA will stop development of vaccine soon

India has sufficient capacity and any new vaccine will not get EUA

ORMP should focus on oral diabetes pill - if successful, that is really a game changer
@U6439892 the thing is the technology is what’s clearly important here. Injectable to oral has many applications.
@Klugelinda : Yup. Nadav Kidron mentioned in an interview that if this technology is successful, they could create oral vaccinations of many virus-based vaccinations, like the yearly flu jab for example.
@U6439892 An oral vaccine will promote mucosal immunity which the current RNA vaccines do not and leads to a problem of the vaccinated still being susceptible to infection as immunity lessens with time. An oral vaccine is easy to administer, transport, and store. Who wants to have to go get tested to see if they have Covid and get a one time oral medication that costs hundreds of dollars. It must be administered in a narrow time window to be effective while a vaccine lasts for years and possibly decades.
Oramed is a winner and investors will be rewarded in the near future.
Patients with diabetes have only dreamed of oral insulin.
Chetan Woodun profile picture
@Klugelinda Yes, great stock
rosestanvt profile picture
@Chetan Woodun
Are we talking about an oral vaccine like Polio? That one started as injectable too.
Chetan Woodun profile picture
@rosestanvt Yes, precisely
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About ORMP

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ORMP

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.